Abstract Number: 1317 • 2016 ACR/ARHP Annual Meeting
Do Patients with MRSA-Positive Septic Arthritis Differ Clinically from Non-MRSA-Positive Counterparts?
Do patients with MRSA-positive septic arthritis differ clinically from non-MRSA-positive counterparts? Mary Louise Fowler3, Kevin Byrne3, Sarah B. Lieber1, Andrew Moore2, Robert H. Shmerling1, Ziv…Abstract Number: 1351 • 2016 ACR/ARHP Annual Meeting
Mortality and Prognostic Factors of Pneumocystis Pneumonia in Patients with Connective Tissue Diseases
Background/Purpose: Pneumocystis pneumonia (PCP) is one of the severe opportunistic infections in immunocompromised patients. PCP is still a leading cause of death in patients with…Abstract Number: 1502 • 2016 ACR/ARHP Annual Meeting
Vaccination Program to Prevent Hospital Admissions Due to Serious Respiratory Infections in Rheumatoid Arthritis Patients. Prosprective Study of 294 Patients
Background/Purpose: Patients with Rheumatoid Arthritis (RA) are at increased risk of infections, especially serious respiratory infections. Immunization is a recommended to reduce these complications.…Abstract Number: 1684 • 2016 ACR/ARHP Annual Meeting
Updated Results for Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Background/Purpose: To describe the rates of serious infections (SI) in psoriasis (PsO) pts with psoriatic arthritis (PsA) from PSOLAR, & assess risk with biologic therapy.…Abstract Number: 1925 • 2016 ACR/ARHP Annual Meeting
Interest of Procalcitonin for the Follow-up of ANCA-Associated Vasculitis: Data from a Cohort of 99 Patients
Background/Purpose: The prognosis of the ANCA associated vasculitis (AAV) has improved with the new immunosuppressive treatments but infectious complications remain frequent. Procalcitonin (PCT) is…Abstract Number: 403 • 2016 ACR/ARHP Annual Meeting
High Rate of Serious Infection in Juvenile Idiopathic Arthritis Under Biologic Therapy in a Real Life Setting
Background/Purpose: Most data about infections associated to biologic therapy in juvenile idiopathic arthritis (JIA) derive from registries designed to identify general adverse events that have…Abstract Number: 2049 • 2016 ACR/ARHP Annual Meeting
Serious Infections in RA Offspring Exposed to Tumor Necrosis Factor Inhibitors
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are increasingly used during RA pregnancy. Most of these are actively transported across the placenta, reaching higher fetal than maternal…Abstract Number: 523 • 2016 ACR/ARHP Annual Meeting
Mortality Profile of Patients with Rheumatoid Arthritis in France and Its Change in 10 Years
Background/Purpose: Rheumatoid arthritis (RA) is associated with an excess of mortality. This risk depends on the disease activity, severity and associated comorbidities. Our objective was…Abstract Number: 2079 • 2016 ACR/ARHP Annual Meeting
Incidence and Risk of Pneumocystis Jirovecii Pneumonia Following Rituximab Treatment in Granulomatosis with Polyangiitis in the United States: An Analysis from a National Database
Background/Purpose: Pneumocystis Jirovecii pneumonia (PJP) is a life-threatening complication in granulomatosis with polyangiitis (GPA). Guidelines from EULAR for ANCA-associated vasculitis (AAV) recommend institution of PJP…Abstract Number: 689 • 2016 ACR/ARHP Annual Meeting
Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
Background/Purpose: Tumour necrosis factor alpha inhibitors are effective in reducing inflammation in rheumatic diseases while increasing the risk of infections. We aimed to study the…Abstract Number: 2310 • 2016 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Complication of Infection during the Treatment for Inflammatory Myopathies Complicated with Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is one of the predominant causes of death in polymyositis/dermatomyositis (PM/DM). We have already reported that low PaCO2 and interstitial…Abstract Number: 773 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Severe Infections in Rituximab Treated Patients: Comparison of Systemic Lupus Erythematosus and Inflammatory Myositis
Background/Purpose: The use of Rituximab (RTX) in patients with autoimmune diseases has been associated with an increased incidence of infection and risk factors for this…Abstract Number: 2543 • 2016 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate Administration on the Risk of Infections Among Rheumatoid Arthritis Patients Treated with Anti-TNF in Real-World
Background/Purpose: Methotrexate (MTX) is routinely used among rheumatoid arthritis (RA) patients treated with anti-TNF agents to enhance treatment efficacy and minimize the dose of biologic…Abstract Number: 1000 • 2016 ACR/ARHP Annual Meeting
Subclinical Cytomegalovirus Viremia Is Associated with Increased Nosocomial Infections and Prolonged Hospitalization in Patients with Systemic Autoimmune Diseases
Background/Purpose: Both subclinical cytomegalovirus (CMV) viremia and CMV disease have been associated with adverse outcomes in select immunosuppressed populations, including an increased incidence of other…Abstract Number: 2575 • 2016 ACR/ARHP Annual Meeting
The Presence of Staphylococcal Toxins in the Urine of Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a disease of unknown etiology;with a pathogenesis that is due to a mixture of genetic, immunological and environmental factors. A…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 32
- Next Page »